Connor, Clark & Lunn Investment Management (CC&L)’s Tarsus Pharmaceuticals TARS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.45M | Buy |
+60,495
| New | +$2.45M | 0.01% | 805 |
|
|
2024
Q4 | – | Sell |
-47,060
| Closed | -$1.55M | – | 1630 |
|
|
2024
Q3 | $1.55M | Sell |
47,060
-38,263
| -45% | -$1.26M | 0.01% | 739 |
|
|
2024
Q2 | $2.32M | Sell |
85,323
-11,724
| -12% | -$319K | 0.01% | 611 |
|
|
2024
Q1 | $3.53M | Buy |
97,047
+6,964
| +8% | +$253K | 0.02% | 509 |
|
|
2023
Q4 | $1.82M | Buy |
90,083
+49,382
| +121% | +$1,000K | 0.01% | 694 |
|
|
2023
Q3 | $723K | Buy |
+40,701
| New | +$723K | ﹤0.01% | 925 |
|